Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin

ConclusionsCOMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion.

Source: Journal of Diabetes Investigation - December 16, 2020 Category: Endocrinology Authors: Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyo Tags: CLINICAL TRIAL Source Type: research